Sign inJoin waitlistJoin the waitlist

JE

Jose Esquilin

Physician · Methodist Healthcare System of San Antonio

Credentials: · · ·

History

Methodist Healthcare System of San Antonio
2019–Present

Pediatric Hematology/Oncology
Westchester Medical Center
2011–2014
Pediatrics
Yale-New Haven Hospital
2008–2011
Columbia Univ Coll of Phys & Surgeons
2001–2005

Research

ZFX controls the self-renewal of human embryonic stem cells
PLoS ONE · 2012 · 43 citations
ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia
Cell Reports · 2014 · 25 citations
Zfx facilitates tumorigenesis caused by activation of the Hedgehog pathway
Cancer Research · 2014 · 22 citations

Stuart Weisberg
3 papers · 3 as a resident
AP
Ajay Perumbeti
1 paper · 1 as a fellow
Amanda Grimes
1 paper
Archana Agarwal
1 paper · 1 as a fellow
CY
Catherine Yen
1 paper · 1 as a resident
Cecile Karsenty
1 paper
Cliff Takemoto
1 paper
CJ
Clinton Joiner
1 paper
Gengwen Tian
1 paper · 1 as a resident
JD
Jenny Despotovic
1 paper
Josef Prchal
1 paper
KT
Karina Top
1 paper · 1 as a resident

Clinical trials

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031